Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE014 (NLD) (Dr. Moreau)
· consented 2022-10-07
Adverse events
5
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-08 (study day 17); relationship: not assessed
severe
serious
assessed
2026-08-18
Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-01-24 (study day 94); relationship: N; serious criteria: hospitalization
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-05-18 (study day 208); relationship: N
moderate
assessed
2026-08-18
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-07-14 (study day 265); relationship: N
moderate
assessed
2026-08-18
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-09-11 (study day 324); relationship: N
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.